Jasper Net Tangible Assets vs Total Assets Analysis

JSPR Stock

USD 3.15 0.02 0.64%

Jasper Therapeutics financial indicator trend analysis is infinitely more than just investigating Jasper Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jasper Therapeutics is a good investment. Please check the relationship between Jasper Therapeutics Net Tangible Assets and its Total Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Net Tangible Assets vs Total Assets

Net Tangible Assets vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jasper Therapeutics Net Tangible Assets account and Total Assets. At this time, the significance of the direction appears to have pay attention.

The correlation between Jasper Therapeutics' Net Tangible Assets and Total Assets is -0.82. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Total Assets in the same time period over historical financial statements of Jasper Therapeutics, assuming nothing else is changed. The correlation between historical values of Jasper Therapeutics' Net Tangible Assets and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Jasper Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Tangible Assets i.e., Jasper Therapeutics' Net Tangible Assets and Total Assets go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Total Assets

Total assets refers to the total amount of Jasper Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Jasper Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from Jasper Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jasper Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.At this time, Jasper Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 07/28/2025, Enterprise Value is likely to grow to about 228.7 M, while Selling General Administrative is likely to drop slightly above 13.1 M.

	2010	2023	2024	2025 (projected)
Interest Income	701K	5.2M	5.1M	4.0M
Net Interest Income	701K	5.2M	5.1M	4.0M

Interest Income Net Interest Income

Jasper Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Warrants	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Total Current Assets	Non Current Liabilities Other
Total Assets		0.8	0.9	0.86	0.17	-0.82	-0.77	-0.98	-0.8	0.98	1.0	0.85	0.89	0.29	1.0	0.92	-0.87	-0.41	-0.06	0.91	0.82	0.87	0.32	0.49	1.0	0.39
Other Current Liab	0.8		0.98	0.63	-0.22	-0.89	-0.83	-0.78	-0.93	0.87	0.79	0.71	0.85	-0.06	0.79	0.84	-0.84	-0.56	-0.02	0.84	0.79	0.89	0.37	0.79	0.8	-0.12
Total Current Liabilities	0.9	0.98		0.71	-0.08	-0.94	-0.88	-0.87	-0.94	0.95	0.88	0.83	0.93	0.08	0.88	0.93	-0.91	-0.54	0.01	0.93	0.87	0.93	0.42	0.72	0.89	0.07
Total Stockholder Equity	0.86	0.63	0.71		-0.09	-0.64	-0.43	-0.86	-0.61	0.75	0.88	0.59	0.63	-0.05	0.88	0.78	-0.72	-0.28	-0.55	0.77	0.71	0.76	-0.21	0.37	0.87	0.31
Other Liab	0.17	-0.22	-0.08	-0.09		0.17	-0.05	-0.12	0.25	0.18	0.17	0.16	0.01	0.98	0.17	0.05	0.12	0.3	0.61	0.05	0.02	-0.23	0.5	-0.3	0.16	0.85
Net Tangible Assets	-0.82	-0.89	-0.94	-0.64	0.17		0.87	0.76	0.9	-0.86	-0.78	-0.92	-0.96	-0.01	-0.78	-0.95	0.98	0.45	-0.01	-0.95	-0.89	-0.89	-0.4	-0.58	-0.8	-0.05
Warrants	-0.77	-0.83	-0.88	-0.43	-0.05	0.87		0.76	0.92	-0.86	-0.73	-0.87	-0.89	-0.25	-0.73	-0.82	0.87	0.71	-0.28	-0.82	-0.82	-0.87	-0.65	-0.72	-0.75	-0.11
Net Debt	-0.98	-0.78	-0.87	-0.86	-0.12	0.76	0.76		0.81	-0.95	-0.99	-0.78	-0.83	-0.23	-0.99	-0.85	0.83	0.52	0.13	-0.84	-0.76	-0.89	-0.26	-0.54	-0.99	-0.33
Retained Earnings	-0.8	-0.93	-0.94	-0.61	0.25	0.9	0.92	0.81		-0.86	-0.77	-0.78	-0.87	0.07	-0.77	-0.83	0.9	0.77	0.06	-0.83	-0.82	-0.97	-0.37	-0.83	-0.79	0.11
Accounts Payable	0.98	0.87	0.95	0.75	0.18	-0.86	-0.86	-0.95	-0.86		0.96	0.87	0.92	0.32	0.96	0.92	-0.88	-0.47	0.09	0.92	0.83	0.88	0.48	0.58	0.97	0.31
Cash	1.0	0.79	0.88	0.88	0.17	-0.78	-0.73	-0.99	-0.77	0.96		0.8	0.85	0.28	1.0	0.88	-0.83	-0.4	-0.1	0.88	0.78	0.85	0.28	0.48	1.0	0.39
Non Current Assets Total	0.85	0.71	0.83	0.59	0.16	-0.92	-0.87	-0.78	-0.78	0.87	0.8		0.95	0.33	0.8	0.93	-0.95	-0.36	0.19	0.93	0.85	0.79	0.54	0.37	0.82	0.36
Non Currrent Assets Other	0.89	0.85	0.93	0.63	0.01	-0.96	-0.89	-0.83	-0.87	0.92	0.85	0.95		0.18	0.85	0.92	-0.96	-0.42	0.15	0.93	0.81	0.86	0.53	0.48	0.86	0.15
Other Assets	0.29	-0.06	0.08	-0.05	0.98	-0.01	-0.25	-0.23	0.07	0.32	0.28	0.33	0.18		0.28	0.2	-0.05	0.18	0.69	0.19	0.15	-0.08	0.65	-0.17	0.28	0.82
Cash And Short Term Investments	1.0	0.79	0.88	0.88	0.17	-0.78	-0.73	-0.99	-0.77	0.96	1.0	0.8	0.85	0.28		0.88	-0.83	-0.4	-0.1	0.88	0.78	0.85	0.28	0.48	1.0	0.39
Common Stock Total Equity	0.92	0.84	0.93	0.78	0.05	-0.95	-0.82	-0.85	-0.83	0.92	0.88	0.93	0.92	0.2	0.88		-0.96	-0.37	-0.04	1.0	0.95	0.86	0.34	0.53	0.9	0.33
Retained Earnings Total Equity	-0.87	-0.84	-0.91	-0.72	0.12	0.98	0.87	0.83	0.9	-0.88	-0.83	-0.95	-0.96	-0.05	-0.83	-0.96		0.51	0.06	-0.96	-0.91	-0.92	-0.35	-0.55	-0.85	-0.15
Short Term Investments	-0.41	-0.56	-0.54	-0.28	0.3	0.45	0.71	0.52	0.77	-0.47	-0.4	-0.36	-0.42	0.18	-0.4	-0.37	0.51		0.13	-0.37	-0.49	-0.74	-0.18	-0.85	-0.41	0.24
Non Current Liabilities Total	-0.06	-0.02	0.01	-0.55	0.61	-0.01	-0.28	0.13	0.06	0.09	-0.1	0.19	0.15	0.69	-0.1	-0.04	0.06	0.13		-0.03	-0.11	-0.21	0.9	-0.13	-0.09	0.19
Capital Surpluse	0.91	0.84	0.93	0.77	0.05	-0.95	-0.82	-0.84	-0.83	0.92	0.88	0.93	0.93	0.19	0.88	1.0	-0.96	-0.37	-0.03		0.95	0.86	0.35	0.53	0.9	0.32
Other Current Assets	0.82	0.79	0.87	0.71	0.02	-0.89	-0.82	-0.76	-0.82	0.83	0.78	0.85	0.81	0.15	0.78	0.95	-0.91	-0.49	-0.11	0.95		0.85	0.27	0.65	0.8	0.33
Other Stockholder Equity	0.87	0.89	0.93	0.76	-0.23	-0.89	-0.87	-0.89	-0.97	0.88	0.85	0.79	0.86	-0.08	0.85	0.86	-0.92	-0.74	-0.21	0.86	0.85		0.23	0.77	0.86	0.01
Total Liab	0.32	0.37	0.42	-0.21	0.5	-0.4	-0.65	-0.26	-0.37	0.48	0.28	0.54	0.53	0.65	0.28	0.34	-0.35	-0.18	0.9	0.35	0.27	0.23		0.21	0.29	0.2
Long Term Investments	0.49	0.79	0.72	0.37	-0.3	-0.58	-0.72	-0.54	-0.83	0.58	0.48	0.37	0.48	-0.17	0.48	0.53	-0.55	-0.85	-0.13	0.53	0.65	0.77	0.21		0.49	-0.24
Total Current Assets	1.0	0.8	0.89	0.87	0.16	-0.8	-0.75	-0.99	-0.79	0.97	1.0	0.82	0.86	0.28	1.0	0.9	-0.85	-0.41	-0.09	0.9	0.8	0.86	0.29	0.49		0.39
Non Current Liabilities Other	0.39	-0.12	0.07	0.31	0.85	-0.05	-0.11	-0.33	0.11	0.31	0.39	0.36	0.15	0.82	0.39	0.33	-0.15	0.24	0.19	0.32	0.33	0.01	0.2	-0.24	0.39

Click cells to compare fundamentals

Jasper Therapeutics Account Relationship Matchups

Jasper Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	23.4M	93.7M	48.4M	94.9M	79.9M	67.4M
Other Current Liab	2.6M	3.1M	3.6M	7.3M	10.1M	5.1M
Total Current Liabilities	4.0M	8.0M	7.1M	12.4M	15.2M	8.9M
Total Stockholder Equity	(35.1M)	69.5M	36.0M	78.4M	61.7M	42.5M
Net Debt	(18.2M)	(81.8M)	(34.6M)	(84.1M)	(69.8M)	(73.3M)
Retained Earnings	(36.8M)	(67.5M)	(105.1M)	(169.6M)	(240.9M)	(228.8M)
Accounts Payable	1.4M	3.9M	1.8M	4.1M	4.0M	2.9M
Cash	19.8M	84.7M	38.3M	86.9M	71.6M	60.2M
Non Current Assets Total	2.7M	5.8M	6.6M	6.0M	4.1M	4.6M
Non Currrent Assets Other	643K	990K	1.2M	1.8M	1.2M	1.1M
Other Assets	643K	990K	0.0	1.0	0.9	0.86
Cash And Short Term Investments	19.8M	84.7M	38.3M	86.9M	71.6M	60.2M
Liabilities And Stockholders Equity	23.4M	93.7M	48.4M	94.9M	79.9M	66.6M
Non Current Liabilities Total	54.5M	16.1M	5.3M	4.1M	3.0M	2.8M
Other Current Assets	43K	3.1M	3.5M	1.8M	4.2M	2.4M
Other Stockholder Equity	(42.2M)	137.0M	141.1M	248.0M	302.5M	317.7M
Total Liab	58.5M	24.1M	12.4M	16.5M	18.2M	17.6M
Total Current Assets	20.7M	87.8M	41.7M	88.9M	75.8M	62.7M

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Jasper Net Tangible Assets vs Total Assets Analysis

Net Tangible Assets vs Total Assets

Net Tangible Assets vs Total Assets Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Total Assets

Jasper Therapeutics fundamental ratios Correlations

Jasper Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jasper Therapeutics fundamental ratios Accounts

Additional Tools for Jasper Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.98	Total Assets
Other Stockholder Equity	- 0.97	Retained Earnings
Capital Surpluse	- 0.96	Retained Earnings Total Equity